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The angiogenic mechanism and therapeutic potential of PDGF-CC, a recently discovered member of the VEGF/
PDGF superfamily, remain incompletely characterized. Here we report that PDGF-CC mobilized endothelial 
progenitor cells in ischemic conditions; induced differentiation of bone marrow cells into ECs; and stimu-
lated migration of ECs. Furthermore, PDGF-CC induced the differentiation of bone marrow cells into smooth 
muscle cells and stimulated their growth during vessel sprouting. Moreover, delivery of PDGF-CC enhanced 
postischemic revascularization of the heart and limb. Modulating the activity of PDGF-CC may provide novel 
opportunities for treating ischemic diseases.
Introduction
The PDGF family consists of 4 members: PDGF-AA, PDGF-BB, 
and the newly discovered PDGF-CC and PDGF-DD (1–3). Homo- 
and heterodimers of these ligands bind, with distinct selectiv-
ity, dimeric complexes of the receptor tyrosine kinases PDGF-
Rα and PDGF-Rβ (4). PDGF-AA selectively binds PDGF-Rαα; 
PDGF-BB binds PDGF-Rαα, -Rββ, and -Rαβ; while PDGF-CC 
binds PDGF-Rαα and -Rαβ (1, 5). In the vessel wall, PDGF-Rα and 
-Rβ are expressed on mural cells, i.e. pericytes and smooth muscle 
cells (SMCs), and activation by PDGF-AA or -BB stimulates the 
growth and migration of these cells (6–12). By recruiting PDGF-Rβ+ 
mural cells, PDGF-BB, secreted by ECs, plays an essential role 
in the maturation of nascent blood vessels and tissue perfusion 
(7–13). PDGF-BB also promotes microvessel growth indirectly by 
stimulating mural cells to produce VEGF (12, 14). As PDGF-AA 
also affects SMCs (6), it might affect angiogenesis indirectly. When 
administered alone, PDGF-BB destabilizes vessels by reducing EC 
survival as a result of impaired mural cell coverage (15), but, when 
coadministered with VEGF or FGF-2, PDGF-BB stimulates revas-
cularization of the ischemic hind limb by promoting vessel growth 
and maturation (16-18). Conversely, inhibition of PDGF-Rα and 
-Rβ signaling blocks angiogenesis in tumors and the ischemic ret-
ina, in part by inducing pericyte detachment (19–23).
The role of PDGF-Rα and -Rβ in regulating ECs remains more 
enigmatic. In vitro, PDGF-BB stimulated the growth and migra-
tion of particular ECs only (24–28), while PDGF-AA failed to 
affect ECs (24, 26–28), even despite PDGF-Rα activation (25). 
This may relate to the fact that PDGF-Rα and -Rβ are present only 
on some, but not on all, ECs (21, 22, 25–27, 29–34). In addition, 
ECs in sprouting vessels express elevated levels of PDGF-Rα and 
-Rβ (22, 25, 33, 34), while PDGF-R expression is downregulated 
in culture (25) or in quiescent vessels in healthy tissues (22). In 
vivo, both PDGF-AA and -BB stimulated microvessel growth in 
the cornea and chorionic allantoic membrane (35–37), but this 
angiogenic effect might be due to an indirect effect on mural 
cells. To complicate matters even more, another study report-
ed that activation of PDGF-Rα by PDGF-AA or -BB inhibited 
FGF-2–induced vessel growth (38).
The angiogenic role of PDGF-CC has been studied only to a 
limited extent. In the avascular mouse cornea, PDGF-CC stim-
ulated microvessel growth, comparably to PDGF-BB but more 
potently than PDGF-AA, possibly because PDGF-CC activates 
PDGF-Rαα and -Rαβ (35). PDGF-CC also induced branching 
of preexisting vessels in the developing embryo (35) but failed 
to affect EC outgrowth from the aorta (5). PDGF-CC stimulates 
SMC growth (1, 5, 39) and induces the release of VEGF (40), 
which suggests that this growth factor induced angiogenesis 
indirectly by affecting mural cells. However, it remains unknown 
whether PDGF-CC is capable of affecting ECs directly. Moreover, 
it is also unknown whether PDGF-CC affects the mobilization or 
differentiation of endothelial progenitors to sites of active vessel 
growth in the adult (a process termed “adult vasculogenesis”). In 
light of the fact that delivery of PDGF-BB alone is not capable of 
stimulating ischemic limb revascularization, it also remains to 
be determined whether single administration of PDGF-CC has 
any therapeutic potential to stimulate revascularization of the 
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ischemic myocardium or limb. We have therefore addressed these 
issues in the present study.
Results
PDGF-CC stimulates vessel growth and maturation in the ischemic heart. 
We used an established mouse model of coronary artery ligation 
to assess whether PDGF-CC stimulates revascularization of the 
ischemic myocardium. By immunostaining (Figure 1, A–C) as 
well as RNAse protection analysis and in situ hybridization (data 
not shown), PDGF-Rα was detectable in a subset of myocardial 
vessels at baseline conditions, but its expression was significantly 
upregulated in the ischemic border zones surrounding the infarcts 
from which new vessels infiltrated the infarct. PDGF-Rα was 
expressed in ECs and SMCs but likely also in additional cell types, 
putatively identified as myofibroblasts and inflammatory cells. 
Immunoprecipitation and subsequent immunoblotting of extracts 
from the microdissected infarct borders further confirmed that 
PDGF-Rα levels were upregulated in the angiogenic regions (Fig-
ure 1D). Moreover, PDGF-Rα was, as assessed by immunoblotting 
of phosphotyrosine (pTyr) residues after immunoprecipitation, 
highly activated in these angiogenic border zones (Figure 1D).
To examine whether PDGF-CC stimulated revascularization 
of the ischemic myocardium, we delivered recombinant human 
PDGF-CC via an osmotic minipump. PDGF-CC increased the 
levels of active PDGF-Rα in the border region (Figure 1D). After 
7 days, angiogenesis in the ischemic area was quantified by 
counting the number of EC-lined vessels after immunolabeling 
with anti-thrombomodulin (anti-TM) antibodies. Vessel matu-
ration (“arteriogenesis”) was evaluated by counting the arteri-
oles immunoreactive for α-SMA. At 1.5 μg/d, PDGF-CC mini-
mally affected the TM+ vessel density (Figure 1, E, G, and H) but 
increased, by 1.4-fold, the number of α-SMA+ arterioles (Figure 1, 
F, J, and K). When 3-fold-higher dose was used, PDGF-CC sig-
nificantly stimulated angiogenesis (Figure 1, E and I) and arte-
riogenesis (Figure 1, F and L). No signs of hemorrhage, edema, 
or fibrosis were observed in PDGF-CC–treated hearts. These new 
vessels were functional, as perfusion of the ischemic myocardial 
region was significantly increased (blood flow: 1.6 ± 0.2 ml/min/g 
in control vs. 2.2 ± 0.2 ml/min/g after treatment with 4.5 μg/d 
PDGF-CC; n = 7–9; P < 0.05). PDGF-CC stimulation of revascu-
larization was restricted to the ischemic heart, as no differences 
were observed in vessel density in other organs (data not shown). 
The magnitude of the potential of PDGF-CC to stimulate revas-
cularization of the ischemic myocardium parallels that of VEGF 
and PlGF (41). The mice tolerated the PDGF-CC treatment with-
out signs of toxicity (weight loss, inactivity). Thus, PDGF-CC 
protein treatment promoted functional revascularization in car-
diac ischemia via enhanced angiogenesis (more vessels) and arte-
riogenesis (more SMC coverage). The angio-/arteriogenic activity 
of PDGF-CC in cardiac ischemia is remarkable, since PDGF-AA, 
another PDGF-Rα ligand, is weakly angiogenic or even suppress-
es angiogenesis (24, 38, 42).
PDGF-CC stimulates vessel growth in the ischemic hind limb. We also 
evaluated whether PDGF-CC stimulated revascularization of 
Figure 1
Therapeutic revascularization with PDGF-CC in ischemic 
heart. (A–C) Immunostaining, revealing low PDGF-Rα 
expression in a subset of microvessels in an uninjured myo-
cardium (A) and strongly increased PDGF-Rα expression in 
sprouting vessels in the border region of a myocardial infarct, 
from where vessels revascularize the infarct (B and C). 
C shows a detail of PDGF-Rα expression in microvessels 
(arrows). (D) Upper and middle panels: immunoprecipitation 
and subsequent Western blotting for PDGF-Rα (upper) and 
pTyr (middle) showed that PDGF-Rα was upregulated in 
the ischemic myocardial regions bordering the infarct where 
vessels start to grow. Note also that PDGF-Rα was acti-
vated more in the borders than the normal (nonischemic) 
regions and maximally after PDGF-CC treatment. Lower 
panel: Coomassie staining revealing comparable loading. 
(E and F) PDGF-CC protein treatment increased TM+ (E) 
and SMA+ (F) vessel density in the infarcted areas in a 
dose-dependent manner. *P < 0.05 vs. vehicle. (G–I) TM 
immunostaining of myocardial vessels, revealing increased 
vessel densities after PDGF-CC treatment. (J–L) α-SMA 
immunostaining of myocardial vessels, revealing increased 
vessel densities after PDGF-CC treatment. Scale bars: 50 
μm in A, B, G–L and 20 μm in C.
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ischemic hind limbs, using an established model (41). We first quan-
tified PDGF-Rα expression in the gastrocnemius muscle, which 
becomes ischemic after ligation of the femoral artery. Two days after 
ligation, when a fraction of myocytes died due to ischemic necrosis, 
PDGF-Rα transcript levels decreased to 76% of those found in nor-
mal muscles (Figure 2A). However, compared with vehicle, a daily 
treatment with 4.5 μg PDGF-CC upregulated PDGF-Rα expression 
at day 2 after ligation and almost completely restored its expression 
levels to values found in the unligated control muscle (Figure 2A). 
Revascularization of the ischemic gastrocnemius muscle after femo-
ral artery ligation was evaluated after 1 week of continuous delivery 
of 4.5 μg/d PDGF-CC. Treatment with PDGF-CC increased both 
the formation and maturation (via coverage by SMCs) of new blood 
vessels (Figure 2, B, C, F, and G). Moreover, PDGF-CC enhanced 
skeletal muscle regeneration (Figure 2, E and H–L) and, as a result, 
also reduced the extent of ischemic muscle necrosis (Figure 2, D and 
H–L), which suggests that muscle regeneration and angiogenesis 
might be linked. PDGF-CC also enlarged the second-generation col-
lateral side branches in the adductor muscle (lumen area: 680 ± 40 
μm2 after saline vs. 920 ± 100 μm2 after PDGF-CC; n = 10; P = 0.05). 
No signs of hemorrhage, edema, or fibrosis were observed in the 
PDGF-CC–treated limbs. Thus, PDGF-CC stimulates revasculariza-
tion in mouse models of both heart and limb ischemia.
PDGF-CC mobilizes endothelial progenitors. To examine how PDGF-
CC stimulates vessel growth, we studied the recruitment of 
endothelial progenitor cells (EPCs). EPC mobilization was quan-
tified by counting the number of cells positive for 1,1′-diocta-
decyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate–acety-
lated LDL (DiI-ac-LDL)/isolectin B4 at 3 weeks after after spleen 
mononuclear cells were plated. Evaluated at the time point of 3 
weeks, only late-outgrowth EPCs, but not surviving sloughed-off 
ECs, are selectively assayed (43). In baseline conditions, PDGF-CC 
did not mobilize EPCs (Figure 3A), consistent with our observa-
tion that PDGF-CC only affected vessel growth in ischemic tis-
sues. However, after femoral artery ligation, administration of 
4.5 μg/d PDGF-CC significantly augmented EPC mobilization 
— the effect being maximal at 2 days (Figure 3A). We then com-
pared the relative efficacy of the different PDGF forms side-by-
side by administering the same dose of PDGF-AA, -BB, or -CC 
(4.5 μg/d) to ligated mice and quantifying the number of mobi-
lized EPCs. Both PDGF-AA and -CC mobilized EPCs at 2 days after 
limb ischemia, while PDGF-BB only insignificantly affected EPC 
Figure 2
Therapeutic revascularization with PDGF-CC in ischemic limbs. (A) RNAse protection analysis, showing that PDGF-Rα expression in the 
gastrocnemius muscle was decreased at 2 days after femoral artery ligation but restored to normal levels after PDGF-CC treatment. The ratio 
of the PDGF-Rα levels (arbitrary units), normalized for β-actin levels, is shown. (B and C) PDGF-CC protein treatment increased the PECAM 
capillary (B) and α-SMA+ arteriolar (C) density in the ischemic gastrocnemius muscle. (D and E) PDGF-CC protein treatment decreased muscle 
necrosis (D) and increased muscle regeneration (E) in the gastrocnemius muscle at 7 days after femoral artery ligation. Areas are percentage 
of total muscle area. *P < 0.05 (A–E). (F and G) Compared with vehicle (F), PDGF-CC protein treatment increased the density of PECAM ves-
sels in the regenerating areas of the ischemic gastrocnemius muscle (G). No signs of edema, hemorrhage. or fibrosis were observed. (H and I) 
H&E staining, showing larger areas of regenerating myocytes (small cells with central nuclei) after PDGF-CC treatment (I) than after treatment 
with vehicle (H). The regions containing regenerating myocytes are surrounded by a dashed black line in both panels. (J–L) Higher magnifica-
tion of H&E-stained sections of a normal gastrocnemius muscle (J); ischemic muscle, treated with vehicle, containing numerous necrotic ghost 
myocytes, and few blood vessels (K); ischemic muscle, treated with PDGF-CC, containing numerous regenerating myocytes with a central 
nucleus and numerous blood vessels (L). Values are mean ± SEM of at least 15 mice. The lumen of the arterioles is filled with dark bismuth 
gelatin in F–L. Scale bars: 50 μm.
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mobilization. The numbers of EPCs per millimeter squared were: 
490 ± 140 after treatment with vehicle, 940 ± 130 after PDGF-AA 
(n = 12; P < 0.05), 640 ± 90 after PDGF-BB (n = 12; P = NS), and 
990 ± 140 after PDGF-CC (n = 12; P < 0.05). In addition, late-out-
growth EPCs expressed PDGF-Rα as revealed by real-time quanti-
tative RT-PCR analysis (25 ± 5 mRNA copies PDGF-Rα per 1,000 
mRNA copies β-actin; n = 3). Moreover, labeling of the cultured 
cells with the anti–PDGF-Rα antibody revealed that the round, 
cobblestone-like Ac-LDL+ EPCs expressed detectable levels of 
PDGF-Rα (Figure 3, B–D). Thus, PDGF-CC enhanced EPC mobili-
zation in conditions of tissue ischemia, thereby providing a source 
of ECs for building new blood vessels.
PDGF-CC promotes differentiation of bone marrow progenitors. To 
investigate the potential role of PDGF-CC in the differentia-
tion of bone marrow progenitors into vascular cells, we cultured 
human bone marrow–derived AC133+CD34+ cells — a population 
enriched for stem/progenitor cells (44) — and stimulated them 
with PDGF-CC, using VEGF as control (50 ng/ml each). After 2 
weeks, both PDGF-CC and VEGF enhanced the adherence of these 
cells — a prerequisite for anchorage-dependent cell differentiation 
and growth (adherent cells, % of vehicle control: 230% ± 30% for 
VEGF; 180% ± 25% for PDGF-CC; P < 0.05). However, the 2 factors 
markedly differed in their ability to induce the commitment of 
these progenitors into either ECs or SMCs. Both PDGF-CC and 
VEGF induced the expression of the EC surface markers vascu-
lar endothelial cadherin (VE-cadherin) (CD144; Figure 3, H–J) 
and CD31 (platelet endothelial cell adhesion molecule [PECAM]; 
Figure 3, K–M). Though these progenitors cells expressed PDGF-Rα 
(RT-PCR analysis; data not shown), some of the effect of PDGF-CC 
to induce an EC phenotype may be attributable to the upregulation 
of VEGF by PDGF-CC in the progenitor cell population (ratio of 
VEGF to TATA box–binding protein mRNA copies: 0.43 ± 0.09 
in control vs. 0.81 ± 0.08 after treatment with PDGF-CC; n = 5; 
P < 0.05). Interestingly, only PDGF-CC additionally induced the 
expression of the SMC marker α-SMA, which indicates that these cells 
had acquired a characteristic SMC phenotype (Figure 3, N and P). 
Notably, this effect of PDGF-CC was specific, as VEGF-treated 
cells did not become α-SMA positive (Figure 3O). Even though 
SMCs release VEGF in response to PDGF-CC (see below), most 
of the PDGF-CC–treated cells became α-SMA positive and lost 
their expression of VE-cadherin and CD31 by 4 weeks of stimula-
tion. VEGF-treated cells, instead, were still VE-cadherin and CD31 
positive but remained α-SMA negative (data not shown). Thus, 
PDGF-CC initially induced bone marrow progenitor cells to differ-
entiate into ECs — eventually, after long-term treatment, yielding 
cells with an SMC-like phenotype.
PDGF-CC promotes EC migration and microvessel sprouting. Expres-
sion of PDGF-Rα on ECs has been observed in some studies but 
not in others (21, 22, 25–27, 29–34). In addition, little is known 
about the functional consequences of PDGF-Rα signaling in 
these cells. We therefore analyzed the effect of PDGF-AA, -BB, 
and -CC on migration and proliferation of several EC types, 
using various assays. As ECs are known to express low levels of 
PDGF-Rα, we enriched cell lysates for PDGF-Rs by using wheat 
germ agglutinin–sepharose (WGA-sepharose) before immuno-
blotting. Both human microvascular ECs (HMVECs) and human 
umbilical venous ECs (HUVECs) expressed detectable levels of 
PDGF-Rα, which was tyrosine phosphorylated upon PDGF-CC 
treatment (data not shown), whereas PDGF-Rβ was undetectable 
(Figure 4A). In a first assay, growth-arrested confluent HMVEC 
monolayers were wounded with a rubber policeman and then 
incubated for 20 hours in serum-free medium containing the 
indicated ligand. Under those conditions, VEGF and PDGF-CC 
strongly stimulated migration of HMVECs (Figure 4B). PDGF-AA 
had a slight effect, whereas PDGF-BB was completely ineffective 
(Figure 4B). The chemotactic effect of PDGF-CC was not restrict-
ed to HMVECs only, as PDGF-CC also enhanced the migration 
of bovine aorta ECs (BAECs; data not shown). The chemotactic 
effect of PDGF-CC was confirmed using HUVECs in the Boyden 
Figure 3
Effects of PDGF-CC on endothelial progenitors. (A) PDGF-CC treat-
ment increased EPC mobilization from day 2 to day 5 after hind limb 
ischemia but did not affect EPC mobilization in normal conditions. 
*P < 0.05. Values are mean ± SEM of 10 mice. (B–D) Double labeling 
of EPCs for PDGF-Rα (green in B) and Dil-ac-LDL (red in C), showing 
coexpression (yellow in D). (E–P) After 2 weeks of stimulation, both 
PDGF-CC and VEGF induced the expression of EC surface markers 
CD144 (VE-cadherin) and CD31 (PECAM), while vehicle-treated cells 
remained negative. Only PDGF-CC induced prominent α-SMA expres-
sion, while cells treated with VEGF or vehicle displayed background 
levels of α-SMA expression. Unstained cells in E–G show that both 
VEGF and PDGF-CC promoted stem/progenitor cell adherence.
research article
122 The Journal of Clinical Investigation   http://www.jci.org   Volume 115   Number 1   January 2005
chamber assay (Figure 4C). PDGF-AA also stimulated endothelial 
migration, while PDGF-BB was again ineffective (Figure 4C).
These findings were further extended by analyzing in the Boy-
den chamber chemotaxis of porcine aortic ECs (PAECs) stably 
overexpressing PDGF-Rα (PAEC/Rα) or PDGF-Rβ (PAEC/Rβ) (45). 
At 125 ng/ml, PDGF-CC was more potent than PDGF-AA in stim-
ulating chemotaxis of PAEC/Rα, whereas PDGF-BB had no effect 
(chemotactic response, % of vehicle: 260% ± 29% for PDGF-AA; 
92% ± 11% for PDGF-BB, and 610% ± 30% for PDGF-CC; P < 0.05, 
PDGF-AA vs. PDGF-CC). As expected, PDGF-AA and -CC failed to 
affect PAEC/Rβ (chemotactic response, % of vehicle: 111% ± 5% for 
PDGF-AA; 101% ± 30% for PDGF-CC), while PDGF-BB induced 
a strong chemotactic response (% of vehicle: 422% ± 22% for 
PDGF-BB; P < 0.05 vs. control). However, none of the PDGFs 
(type AA, BB, or CC) affected proliferation of HMVECs (Figure 
4D), BAECs, or HUVECs (data not shown), in agreement with the 
previous observation that PDGF-Rα does not transmit mitogenic 
signals in response to PDGF-AA in ECs (25). VEGF, instead, highly 
stimulated EC proliferation (Figure 4D).
We also tested the effect of PDGF-CC on cultured aortic rings, 
as this assay allows assessing the outgrowth of microvessels 
from an intact vessel in vitro (46). After 9 days of culturing the 
rings with or without 30 ng/ml ligand, the microvessels and 
the perivascular myofibroblasts, growing out of the aorta, were 
counted. Only PDGF-CC, but not PDGF-AA or -BB, stimulated 
microvessel outgrowth (Figure 4, E, F, and H). Each PDGF form 
did, however, increase myofibroblast outgrowth, but PDGF-CC 
was the most potent (Figure 4I). VEGF only stimulated microves-
sel growth, without affecting myofibroblast emigration (Figure 
4, G–I). Vessel outgrowth in response to PDGF-CC was large-
ly blocked (i.e., by 80%) by supplementation of a neutralizing 
anti-VEGF antibody, which indicates that at least some of the 
angiogenic effect of PDGF-CC in this assay was mediated via 
VEGF release. Indeed, following stimulation with 50 ng/ml 
PDGF-CC, cultured SMCs released increased amounts of VEGF 
in the conditioned medium (24 ± 1 pg/105 cells/24 h, after treat-
ment with control vs. 35 ± 1 pg/105 cells/24 h, after treatment 
with 50 ng/ml PDGF-CC; n = 4; P < 0.05). This effect was spe-
cific, as 50 ng/ml PDGF-AA failed to stimulate VEGF expres-
sion (22 ± 1 pg/105 cells/24 h; n = 4; P = NS vs. control). Thus, 
PDGF-CC is capable of stimulating angiogenesis via direct and 
indirect effects on ECs.
Tyrosine phosphorylation of PDGF-Rα in response to PDGF-CC. 
Although PDGF-AA, -BB, and -CC bind PDGF-Rα, these ligands 
did not always induce an identical response, for example, in EPC 
recruitment, EC migration, microvessel and myofibroblast out-
growth from the aortic ring, or induction of VEGF release. We 
therefore studied whether activation of PDGF-Rα and tyrosine 
Figure 4
Effect of PDGF-CC on EC migration and 
outgrowth of microvessels. (A) WGA pre-
cipitation and subsequent immunoblotting 
of extracts of control and ligand-stimulated 
HUVECs and HMVECs, revealing detect-
able expression of PDGF-Rα but not of 
PDGF-Rβ. By immunoblotting, PDGF-Rα 
was tyrosine phosphorylated in both cell 
lines (data not shown). (B and C) In the 
scrape wound assay (B), PDGF-CC stimu-
lated HMVEC migration with a potency 
similar to that of VEGF, while PDGF-AA 
and -BB had an intermediate or no effect, 
respectively. In the Boyden chamber assay 
(C), both PDGF-AA and -CC induced 
HUVEC chemotaxis, while PDGF-BB was 
inactive. (D) None of the PDGFs affected 
HMVEC proliferation, while VEGF potent-
ly promoted cell proliferation. *P < 0.05. 
Values are mean ± SEM. RLU, relative 
luminescence units. (E–G) Micrographs 
of aortic rings, displaying microvascular 
sprouts and perivascular cells. Compared 
to vehicle (E), PDGF-CC enhanced the 
outgrowth of both microvascular sprouts 
and fibroblast-like cells (F), while VEGF 
stimulated microvascular outgrowth (G). 
(H and I) In the aortic ring assay, PDGF-CC 
and VEGF induced microvessel outgrowth, 
while PDGF-AA and -BB were inactive (H). 
Each PDGF form stimulated myofibroblast 
outgrowth from the aortic ring, but PDGF-
CC was more potent than PDGF-BB and 
PDGF-AA, whereas VEGF was inactive (I). 
P < 0.05 (H and I). WB, Western blot.
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phosphorylation of downstream proteins by PDGF-AA, -BB, and 
-CC in ECs was different. Since PDGF-Rα levels in primary ECs 
are insufficient to permit reliable detection of PDGF-Rα tyro-
sine phosphorylation, we used PAEC/Rα (45). After stimulation 
of these cells with each ligand at 10, 30, and 100 ng/ml for 10 
minutes, equal amounts of cell extracts were immunoprecipitated 
with anti–PDGF-Rα antibodies and subsequently immunoblotted 
with pTyr-specific and PDGF-Rα–specific antibodies. Specific 
bands were then densitometrically quantified, and the PDGF-Rα–
pTyr/PDGF-Rα ratio was calculated. At all concentrations tested, 
PDGF-AA stimulated tyrosine phosphorylation of PDGF-Rα less 
than PDGF-BB and -CC (Figure 5A). After quantification, the 
PDGF-Rα–pTyr/PDGF-Rα ratio increased 3.3 ± 0.5-, 4.6 ± 0.2-, 
and 5.6 ± 1.0-fold when cells were treated with 10, 30, and 100 
ng/ml PDGF-AA, respectively (n = 3–7; P < 0.05), while this ratio 
increased 9 ± 1-, 13 ± 3-, and 23 ± 5-fold after stimulation with 10, 
30, and 100 ng/ml PDGF-CC, respectively (n = 3–7; P < 0.05 vs. 
PDGF-AA by ANOVA with Bonferroni correction). Correspond-
ing values for PDGF-BB were 18 ± 2-, 20 ± 2-, and 44 ± 8-fold, 
respectively (n = 3; P < 0.05 vs. PDGF-AA by ANOVA). Thus, at 
least in PDGF-Rα–expressing PAECs, PDGF-BB and -CC induced 
a higher degree of PDGF-Rα activation than PDGF-AA. We also 
analyzed whether PDGF-AA, -BB, and -CC affected downstream 
signaling differently. Therefore, equal amounts of total cell lysates 
from PAEC/Rα, stimulated with 10 or 100 ng/ml PDGF-AA, -BB, 
or –CC for 10 minutes, were immunoblotted using the PY99 pTyr 
antibody. At least when identifying the phosphorylated proteins 
on the basis of their molecular weight, PDGF-AA, -BB, and -CC 
seemed to stimulate tyrosine phosphorylation of a similar panel of 
downstream targets (Figure 5B). However, at both concentrations, 
PDGF-BB and -CC generally induced stronger phosphorylation 
signals than did PDGF-AA.
Discussion
Study of the role of PDGF-CC in angiogenesis in vivo has been 
limited. One study reported that PDGF-CC has no effects on 
EC outgrowth from the aorta (5), while another documented 
effects of PDGF-CC on microvessel outgrowth and branching in 
the mouse cornea and chicken embryo (35). From these studies, 
PDGF-CC seemed to affect ECs indirectly via effects on SMCs 
(1, 5, 39), in part by inducing the release of VEGF (40). Direct 
effects of PDGF-CC on ECs or their progenitors have not been 
reported thus far. Here, we show that PDGF-CC stimulates the 
recruitment of endothelial progenitors from the bone marrow. 
Numerous studies have documented that adult bone marrow–
derived progenitor cells can contribute to the revascularization 
of and, thereby, facilitate the regeneration and functional recov-
ery of the ischemic limb and heart. However, the signals that 
trigger their mobilization and induce their differentiation into 
more specialized vascular cells remain more enigmatic. In the 
present study, we found that PDGF-CC mobilizes EPCs within 
the first 2 days and up to 5 days after tissue ischemia. This is 
precisely the time window within which new blood vessels start 
to grow in these ischemic tissues.
EPCs were found to express PDGF-Rα mRNA transcript and 
protein, which indicates that they respond to PDGF-CC. Our 
findings obviously do not exclude the possibility that PDGF-CC 
may also affect EPC mobilization indirectly via upregulation of 
additional mobilization signals, such as VEGF. In fact, many cell 
types, including bone marrow–derived EPCs and SMCs (the pres-
ent study), fibroblasts (data not shown and ref. 47), and tumor 
cells (40) release VEGF in response to PDGF-CC, which suggests 
Figure 5
Tyrosine phosphorylation of PDGF-Rα and downstream proteins in 
response to PDGF-CC. (A) Immunoprecipitation of equal amounts of 
PAEC/Rα extracts for PDGF-Rα and subsequent immunoblotting for 
pTyr, revealing a higher degree of PDGF-Rα tyrosine phosphorylation 
after 10-minute stimulation with PDGF-BB or -CC than with PDGF-AA. 
The lower panel shows an immunoblot of PDGF-Rα, displaying the 
amount of receptor present in each sample. (B) Immunoblotting of equal 
amounts of PAEC/Rα extracts for pTyr after stimulation with PDGF-AA, 
-BB, or -CC for 10 minutes, revealing that a similar set of proteins 
(judged on the basis of their molecular weight) was phosphorylated 
but that, in general, the phosphorylation signals were stronger in 
response to PDGF-BB and -CC than PDGF-AA. The lower panel shows 
an immunoblot of PDGF-Rα, displaying the amount of receptor pres-
ent in each sample. For both A and B, though equal amounts of cell 
lysate were immunoprecipitated (A) and/or loaded (A and B), PDGF-Rα 
levels differed among the various lanes, presumably reflecting effects 
on receptor internalization and degradation. PDGF-Rα is present as a 
doublet due to differences in glycosylation.
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that direct and indirect effects might be involved. As PDGF-CC 
only stimulated the mobilization of EPCs after induction of limb 
ischemia, additional recruitment signals, induced by ischemia, 
are likely involved.
PDGF-BB stimulates vascular progenitors to acquire an SMC 
phenotype in the embryo and adult, but the effect of PDGF-CC 
had never been studied. Here, we show that PDGF-CC promoted 
AC133+CD34+ progenitors to differentiate into cell types with 
EC or SMC markers. VEGF, instead, only promoted these pro-
genitors to differentiate into ECs. PDGF-CC initially promoted 
the differentiation of both lineages but subsequently, after pro-
longed treatment, favored the differentiation of SMCs. The activ-
ity of PDGF-CC to induce an endothelial phenotype may be due 
to direct effects on these progenitors (as they express PDGF-Rα) 
but also to indirect effects via release of VEGF by the progenitors 
themselves. Our data do not allow us to distinguish between the 
possibilities that PDGF-CC stimulated the transdifferentiation 
of ECs to SMCs or that it enhanced the selection of SMCs start-
ing from a single population of a common vascular progenitor or 
from a mixed population of endothelial and SMC progenitors. A 
possible implication of these findings is that when only VEGF is 
present, bone marrow–derived progenitors will preferentially con-
tribute to the formation of endothelial capillaries. Instead, when 
PDGF-CC is present, it might favor their differentiation into both 
ECs and SMCs and, thereby, promote not only the formation but 
also the stabilization of nascent vessels.
The activity of PDGF-CC is, however, not restricted to vascular 
progenitors only. Indeed, this growth factor also stimulated the 
migration of differentiated ECs — both when studied as isolated 
cultured cells (by scrape wounding and Boyden chamber assays) 
and in the aortic ring assay. Such an effect on ECs has not been 
reported previously. There may be several explanations for this. 
For instance, the fact that several studies did not detect PDGF-Rα 
or -Rβ on cultured ECs may relate to the finding that PDGF-R 
expression is downregulated in culture and that PDGF-Rs are 
expressed only by some but not all EC types (22, 25, 26, 30, 32, 
33). Moreover, detection of the low PDGF-R levels in cultured 
ECs requires sensitive precipitation and immunoblotting tech-
niques. Using WGA for precipitation permitted us to detect the 
low levels of PDGF-Rα on HMVECs and HUVECs. Importantly, 
however, PDGF-Rα expression in cultured ECs is not an in vitro 
artifact, as PDGF-Rα is present on ECs in the heart and, in par-
ticular, upregulated in inflamed and ischemic areas of new vessel 
growth. These findings are consistent with previous reports that 
PDGF-Rα is expressed in tumor areas with active vessel growth 
but not in quiescent endothelium (22, 30, 48). It thus seems that 
PDGF-Rα expression is highly regulated in vivo and that such 
complex regulation might be preserved or lost in vitro, perhaps 
depending on experimental conditions such as the serum, the pas-
sage number and type of ECs, etc. Overall, the effects of PDGF-CC 
on ECs observed in this study suggest that PDGF-CC stimulates 
angiogenesis in part by affecting ECs directly.
PDGF-AA, -BB and -CC all bind PDGF-Rα, yet they did not induce 
identical biological responses. For instance, PDGF-AA and -CC 
mobilized EPCs more efficiently than PDGF-BB, while PDGF-AA 
and -BB were less potent than PDGF-CC in stimulating migration 
of ECs in wounded monolayers. Furthermore, PDGF-CC was more 
effective than PDGF-AA and -BB in stimulating microvessel out-
growth and myofibroblast emigration from the aorta. How can 
these differences be explained? One possible explanation is that 
PDGF-BB and -CC, but not PDGF-AA, are capable of transmitting 
signals via PDGF-Rβ, when PDGF-Rβ is coexpressed with PDGF-Rα 
in ECs. PDGF-Rβ was, however, undetectable in our ECs, and 
thus the effect of PDGF-BB or -CC would not be expected to be 
mediated via PDGF-Rαβ or -Rββ. These findings therefore raise 
the question of whether PDGF-AA, -BB, and -CC differ in their 
ability to stimulate, quantitatively or qualitatively, PDGF-Rα — a 
provocative question that cannot be conclusively addressed by 
our present findings. When PAEC/Rα was used, PDGF-AA stim-
ulated tyrosine phosphorylation of PDGF-Rα and downstream 
proteins less than PDGF-BB or -CC, but it remains to be estab-
lished whether this is also true for nontransfected ECs expressing 
physiological levels of PDGF receptors. Alternatively, we also can-
not exclude the possibility that yet another coreceptor is involved 
in the response to some of the PDGFs. Whatever the mechanism, 
the distinct complementary biological activities of PDGF-AA, 
-BB, and -CC may further help to explain why loss of pdgf-rα 
causes a more severe phenotype than that caused by elimination 
of the pdgf-a gene alone (1, 49) and why only the combined loss of 
the pdgf-a and -c genes phenocopied the loss of pdgf-rα (50).
PDGF-CC treatment mobilized endothelial progenitors and 
increased the vessel density and blood perfusion in the isch-
emic heart and limb but did not affect quiescent vessels in other 
organs. Although PDGF-CC enlarged the second-generation side 
branches of the collateral vessels in the adductor muscle, this 
growth factor has, overall, a less dramatic effect on the remod-
eling of the preexisting collaterals in the upper limb region 
after femoral artery ligation than, for instance, bFGF, PlGF, or 
GM-CSF (41, 51). However, the molecular and cellular mecha-
nisms of the growth of collateral vessels are quite distinct from 
those determining the formation of new capillaries and their mat-
uration by coverage with SMCs. In particular, not ischemia but 
shear stress–induced recruitment of monocytes/macrophages is 
well known to play a critical role in initiating collateral growth 
in the upper hind limb (51), and PDGF-CC does not affect their 
recruitment (data not shown). Since only the lower, but not the 
upper, limb is ischemic after femoral artery ligation, PDGF-CC 
seems to be more involved in ischemia-dependent angiogenesis 
than in the shear stress–induced collateral vessel remodeling. 
Our findings that PDGF-CC is more effective in ischemic than 
nonischemic tissues do not exclude the possibility that PDGF-CC 
might affect vessel growth in nonischemic tissues. PDGF-CC did, 
for instance, stimulate angiogenesis in the chick embryo (35). 
But in the adult, PDGF-CC has thus far only been documented 
to enhance angiogenesis in the avascular — and therefore isch-
emic — cornea (35), which supports our present findings.
Despite the initial lack of success in clinical trials, therapeutic 
revascularization of ischemic tissues is still an outstanding and 
medically important goal. Forming new blood vessels via admin-
istration of a single angiogenic factor has, apparently, been more 
challenging than initially considered. Of the members of the 
PDGF family, only PDGF-BB has been evaluated thus far. When 
administered alone, PDGF-BB may cause vessel regression due to 
endothelial apoptosis as a result of impaired mural cell recruit-
ment (15, 16, 18). When coadministered with FGF-2 or VEGF, 
PDGF-BB promotes the formation of more numerous and stable 
vessels (16–18). In comparison, administration of PDGF-CC alone 
sufficed to stimulate new vessel growth and maturation, but it 
remains to be evaluated whether coadministration with other 
angiogenic factors will not induce a greater response. As exces-
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sive and protracted overexpression of PDGF-CC to levels many 
fold higher than used in the present study may be implicated in 
organ fibrosis (e.g., heart, liver) via uncontrolled stimulation of 
fibroblasts (47, 52), caution is warranted to carefully optimize the 
dose and duration of the administration of this growth factor in 
order to selectively induce vessel growth and maturation without 
causing profibrotic effects.
In conclusion, PDGF-CC may stimulate vessel growth in vari-
ous ways: apart from inducing the release of VEGF, it also mobi-
lizes vascular progenitors and promotes their differentiation into 
ECs and SMCs, stimulates EC migration, and affects SMCs. These 
effects of PDGF-CC on vascular and muscle regeneration, togeth-
er with its safety profile and activity in ischemic conditions, may 
have implications for developing novel strategies for the treat-
ment of heart and limb ischemia.
Methods
Mouse ischemia models. Myocardial and hind limb ischemia mouse models, 
protein delivery, blood flow measurements, histology, and morphometric 
quantification of vessel densities were all performed as described (41). 
PDGF-CC was produced in-house as described (1). Gastrocnemius mus-
cles were harvested 7 days after femoral artery ligation, and sections were 
analyzed after H&E staining or immunostaining for the EC marker CD31 
(rat anti-CD31; BD Biosciences — Pharmingen). Vessel densities and tis-
sue necrosis/regeneration were morphometrically analyzed using KS300 
image analysis software (Carl Zeiss Inc.). PDGF-Rα transcript levels were 
detected by in situ hybridization, as described (53). PDGF-Rα protein was 
visualized on paraformaldehyde-fixed cryosections of the heart using a 
PDGF-Rα–specific antibody (rabbit anti-human PDGF-Rα, called R7, 
raised against the C-terminal amino acid residues 1066–1084 of PDGF-Rα; 
ref. 54). Procedures involving experimental animals were approved by the 
Institutional Animal Care and Research Advisory Committee of the Univ-
eristy of Leuven, Leuven, Belgium (P02047 and P02046).
EPC mobilization assay. Mice were treated with vehicle (PBS), PDGF-AA 
(R&D Systems), PDGF-BB (54), or PDGF-CC (1) (4.5 μg/d) immediately 
after femoral artery ligation using osmotic minipumps and, after 2 or 5 days, 
spleen mononuclear cells were plated out for EPC analysis as described (55). 
Late-outgrowth EPCs (after 3 weeks of culture) were identified by metabolic 
uptake of DiI-ac-LDL (Molecular Probes) and positive staining of Alexa 488–
labeled isolectin B4 (Molecular Probes Inc.). EPC densities of 5 microscopic 
fields at ×200 magnification (using a confocal microscope) were determined 
and averaged by an investigator blinded to the treatment.
Human bone marrow–derived AC133+CD34+ cells. Enriched bone mar-
row–derived AC133+CD34+ cells (BioWhittaker) were seeded in a 6-well 
collagen-coated plate (BD) and cultured for 3 days in hematopoietic 
growth medium (BioWhittaker) supplemented with 4% FCS (Invitrogen 
Corp.), thrombopoietin (50 ng/ml), SCF (25 ng/ml), and Flt-3 ligand 
(50 ng/ml; R&D Systems). The cultures were depleted of any contaminat-
ing stromal fibroblasts by subculturing, after 3 days, the nonadherent 
fraction of AC133+CD34+ cells at 105 cells/ml in collagen-coated 12-well 
plates in endothelial basal medium (BioWhittaker) containing 4% FCS 
and 50 ng/ml VEGF165 (R&D Systems) or PDGF-CC. Growth factors were 
added every 2 days, and media were refreshed for 75% every 4 days. For the 
adherence assay, 2.5 × 104 nonadherent cells/ml were cultured in the same 
condition on collagen-coated chamber slides or in 96-well plates coated 
with 0.3% gelatin in PBS. After 2 weeks of culture, cells were stained with 
Giemsa May-Grünwald reagent. The number of viable cells was estimated 
by ATP quantification using the CellTiter-Glo Luminescent Cell Viabil-
ity Assay (Promega Corp.). For cell surface stainings, cells (2 × 104/well) 
cultured on collagen-coated culture slides, were fixed, permeabilized 
using the IntraStain Kit (DakoCytomation), and labeled with CD31-FITC 
(BD), CD144-FITC (BD Biosciences — Pharmingen), CD34-FITC (BD), or 
α-SMA–Cy3 (Sigma-Aldrich). Labeled cells were analyzed using laser con-
focal immunofluorescence microscopy.
Cell migration, proliferation and aortic ring assay. To study EC migration, 2 
assays were used. In the scrape wounding assay, growth-arrested confluent 
HMVEC or BAEC monolayers were wounded with a rubber policeman and 
washed with serum-free medium. Dishes were incubated for 20 hours in 
serum-free medium containing 50 ng/ml VEGF165 or PDGF-AA, -BB, or 
-CC. The area of migrating cells was determined as percentage of the total 
wound area. The modified Boyden chamber assay was performed using a 
48-multiwell microchemotaxis chamber (AP48; Neuro Probe Inc.). Poly-
carbonate filters (pore size 8 μm; Neuro Probe Inc.) were coated with 1% 
gelatin for 2 hours at 37°C. Subconfluent cells were prepared in serum-free 
medium at 3 × 105 cells/50 μl. The bottom wells were filled with 28 μl/well 
of chemoattractant diluted in serum-free medium, and 50 μl cell suspen-
sion/well was added to the upper chamber. After incubation at 37°C for 
10 hours, the filters were fixed and, after Giemsa staining, the cells were 
counted in 10 fields per well at ×400 magnification. All the experiments 
were carried out at least 3 times in duplicate.
To determine cell proliferation, 2 assays were used. In the first assay, cells 
were seeded in 96-well plates (5 wells per condition) and incubated with 
VEGF or PDGF-AA, -BB, or -CC (50 ng/ml) after serum starvation. After 
7 days, viable cells were counted using the CellTiter-Glo Luminescent Cell 
Viability Assay. In the second assay, subconfluent HMVECs and HUVECs 
were trypsinized and seeded at 4,000 cells/well in 1% gelatin-coated 
96-well microplates and incubated for 4 hours. After the cells had attached, 
the medium was replaced with serum-free medium containing different 
amounts of PDGF-AA, -BB, or -CC (0, 1, 5, 25, 50, 100, 200 ng/ml). After 
incubation for 24, 48, and 72 hours, 10 μl of Cell Proliferation Reagent 
WST-1 (Roche Diagnostics GmbH) was added to each well and incubated 
for 1 hour, after which the absorbance was measured at 450 nm.
The aortic ring assay was performed as described (46). Briefly, 1-mm-
long aortic rings were embedded in gels of rat tail interstitial collagen, 
cultured at 37°C, supplemented with different growth factors (50 ng/ml) 
or anti-VEGF antibody (AF-493-NA; R&D Systems), and analyzed after 9 
days. Experiments included 3 explants per condition and were repeated 
at least twice. Aortic rings were photographed at ×25 magnification, and 
the number of microvessels or myofibroblasts, emigrating from each aor-
tic ring, was counted (46).
RNA and protein analysis. RNAse protection analysis was performed 
according to the manufacturer’s protocol (Ambion Inc.), and mouse 
β-actin cDNA was used as internal control. Quantitative real-time PCR of 
VEGF and TATA box–binding protein was performed as described (41). 
Secreted VEGF protein was quantified using the Quantikine immunoassay 
kit (R&D Systems) according to the manufacturer’s protocol.
PDGF receptor analysis. PAEC/Rα (45) were starved overnight in serum-
free medium and then stimulated with PDGF-AA, -BB, or -CC at the 
indicated concentration for 10 or 20 minutes. Thereafter, cells were lysed, 
and equal amounts of total cell lysates were immunoprecipitated using 
anti–PDGF-Rα antibodies (sc431; Santa Cruz Biotechnology Inc.). Half 
of the immunoprecipitate was analyzed by Western blotting using anti–
pTyr mAb (PY99; Santa Cruz Biotechnology Inc.), while the other half was 
used to determine the amount of immunoprecipitated receptor, using 
the anti–PDGF-Rα antibody. Either HRP-conjugated goat anti-mouse 
immunoglobulins or HRP-conjugated goat anti-rabbit immunoglobulins 
(DakoCytomation) were used as secondary antibodies. Similar methods 
were used for analysis of PDGF-Rα in tissues.
After overnight starvation in 0.1% FCS, HMVECs and HUVECs (express-
ing lower PDGF-R levels) were treated with 50 ng/ml PDGF-AA, -BB, 
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or -CC for 10 minutes, washed, and lysed. The lysates were cleared by 
centrifugation, and, in order to enrich for PDGF-Rs, WGA-sepharose 
(Amersham Biosciences) was added and incubated under rotation at 4°C 
for 2 hours. After washing, the proteins were eluted by incubation with 
SDS sample buffer for 5 minutes at 95°C, resolved with SDS-PAGE, and 
immunoblotted using the R7/TIE PDGF-Rα antiserum (1:500 dilution) 
(54). Antibodies recognizing pTyr (sc-7020) and PDGF-Rβ (sc-339) were 
from Santa Cruz Biotechnology Inc.
Statistics. Two-tailed Student’s t test was used for data analysis, with 
P < 0.05 considered statistically significant. For cell migration assay, 
ANOVA/Dunnett test was used for data analysis, with P < 0.05 consid-
ered statistically significant.
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